Literature DB >> 34212542

COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group.

Mi Ae Kim1, Yong Won Lee2, So Ri Kim3, Joo Hee Kim4, Taek Ki Min5, Hae Sim Park6, Meeyong Shin7, Young Min Ye6, Sooyoung Lee8, Jeongmin Lee9, Jeong Hee Choi10,11, Gwang Cheon Jang12, Yoon Seok Chang13.   

Abstract

In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience.
Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.

Entities:  

Keywords:  COVID-19; anaphylaxis; hypersensitivity; immunity; immunization; pandemics; preservatives; public health; vaccine

Year:  2021        PMID: 34212542     DOI: 10.4168/aair.2021.13.4.526

Source DB:  PubMed          Journal:  Allergy Asthma Immunol Res        ISSN: 2092-7355            Impact factor:   5.764


  14 in total

Review 1.  Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).

Authors:  Elio Novembre; Mariangela Tosca; Carlo Caffarelli; Mauro Calvani; Fabio Cardinale; Riccardo Castagnoli; Elena Chiappini; Claudio Cravidi; Michele Miraglia Del Giudice; Marzia Duse; Amelia Licari; Sara Manti; Alberto Martelli; Giampaolo Ricci; Giuseppe Pingitore; Gian Luigi Marseglia
Journal:  Ital J Pediatr       Date:  2022-05-16       Impact factor: 3.288

Review 2.  A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.

Authors:  Farnoosh Seirafianpour; Homa Pourriyahi; Milad Gholizadeh Mesgarha; Arash Pour Mohammad; Zoha Shaka; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2022-04-11       Impact factor: 3.858

Review 3.  Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.

Authors:  Linyi Chen; Xianming Cai; Tianshuo Zhao; Bingfeng Han; Mingzhu Xie; Jiahao Cui; Jiayu Zhang; Chao Wang; Bei Liu; Qingbin Lu; Fuqiang Cui
Journal:  Vaccines (Basel)       Date:  2022-04-12

4.  Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers.

Authors:  Valentin Niekrens; Jan Esse; Jürgen Held; Carina Sophia Knobloch; Philipp Steininger; Bernd Kunz; Christof Seggewies; Christian Bogdan
Journal:  Vaccines (Basel)       Date:  2022-04-20

5.  Post COVID-19 vaccine deaths - Singapore's early experience.

Authors:  Audrey Yeo; Benjamin Kuek; Mandy Lau; Shi Rui Tan; Shijia Chan
Journal:  Forensic Sci Int       Date:  2022-01-19       Impact factor: 2.676

6.  The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis.

Authors:  Marharyta Sobczak; Rafał Pawliczak
Journal:  Clin Mol Allergy       Date:  2022-01-17

7.  Cutaneous reactions to COVID-19 vaccine at the dermatology primary care.

Authors:  Martina Burlando; Astrid Herzum; Claudia Micalizzi; Emanuele Cozzani; Aurora Parodi
Journal:  Immun Inflamm Dis       Date:  2021-11-27

8.  Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions.

Authors:  Mitchell M Pitlick; Andrea N Sitek; Michael E D'Netto; Kelley N Dages; Sergio E Chiarella; Alexei Gonzalez-Estrada; Avni Y Joshi; Miguel A Park
Journal:  Ann Allergy Asthma Immunol       Date:  2021-11-16       Impact factor: 6.347

9.  The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine.

Authors:  Marina Labella; Jose Antonio Céspedes; Inmaculada Doña; Mohamed H Shamji; Ioana Agache; Cristobalina Mayorga; Maria José Torres
Journal:  Allergy       Date:  2021-10-31       Impact factor: 14.710

10.  Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?

Authors:  Gerardo Cazzato; Paolo Romita; Caterina Foti; Debora Lobreglio; Irma Trilli; Anna Colagrande; Giuseppe Ingravallo; Leonardo Resta
Journal:  Vaccines (Basel)       Date:  2022-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.